Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. more
Time Frame | MGNX | Sector | S&P500 |
---|---|---|---|
1-Week Return | - | -3.39% | 0.2% |
1-Month Return | -4.84% | -1.92% | 2.72% |
3-Month Return | -0.74% | -10.54% | 7.31% |
6-Month Return | -22.14% | -4.47% | 10.44% |
1-Year Return | -61.52% | 4.06% | 27.53% |
3-Year Return | -79.84% | 0.94% | 30.88% |
5-Year Return | -67.14% | 36.67% | 89.21% |
10-Year Return | -88.58% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 62.02M | 97.76M | 75.64M | 151.94M | 58.75M | [{"date":"2019-12-31","value":40.82,"profit":true},{"date":"2020-12-31","value":64.34,"profit":true},{"date":"2021-12-31","value":49.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.67,"profit":true}] |
Cost of Revenue | 195.31M | 193.20M | 2.65M | 7.38M | 8.22M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.92,"profit":true},{"date":"2021-12-31","value":1.36,"profit":true},{"date":"2022-12-31","value":3.78,"profit":true},{"date":"2023-12-31","value":4.21,"profit":true}] |
Gross Profit | (133.28M) | 97.76M | 72.99M | 144.56M | 50.53M | [{"date":"2019-12-31","value":-92.2,"profit":false},{"date":"2020-12-31","value":67.63,"profit":true},{"date":"2021-12-31","value":50.49,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":34.95,"profit":true}] |
Gross Margin | (214.89%) | 100.00% | 96.50% | 95.14% | 86.00% | [{"date":"2019-12-31","value":-214.89,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.5,"profit":true},{"date":"2022-12-31","value":95.14,"profit":true},{"date":"2023-12-31","value":86,"profit":true}] |
Operating Expenses | 239.21M | 228.82M | 275.79M | 265.98M | 217.22M | [{"date":"2019-12-31","value":86.74,"profit":true},{"date":"2020-12-31","value":82.97,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.44,"profit":true},{"date":"2023-12-31","value":78.76,"profit":true}] |
Operating Income | (177.19M) | (131.06M) | (202.79M) | (121.42M) | (168.24M) | [{"date":"2019-12-31","value":-17718500000,"profit":false},{"date":"2020-12-31","value":-13106000000,"profit":false},{"date":"2021-12-31","value":-20279500000,"profit":false},{"date":"2022-12-31","value":-12141800000,"profit":false},{"date":"2023-12-31","value":-16824400000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | 1.36M | 3.32M | 167.44M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.81,"profit":true},{"date":"2022-12-31","value":1.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (151.81M) | (129.74M) | (202.12M) | (119.76M) | (9.06M) | [{"date":"2019-12-31","value":-15181100000,"profit":false},{"date":"2020-12-31","value":-12973900000,"profit":false},{"date":"2021-12-31","value":-20211500000,"profit":false},{"date":"2022-12-31","value":-11975800000,"profit":false},{"date":"2023-12-31","value":-905800000,"profit":false}] |
Income Taxes | (25.37M) | (11.96M) | (11.26M) | 263.00K | 9.48M | [{"date":"2019-12-31","value":-267.74,"profit":false},{"date":"2020-12-31","value":-126.17,"profit":false},{"date":"2021-12-31","value":-118.79,"profit":false},{"date":"2022-12-31","value":2.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | - | (190.86M) | (120.02M) | (18.54M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-19085700000,"profit":false},{"date":"2022-12-31","value":-12002100000,"profit":false},{"date":"2023-12-31","value":-1853510500,"profit":false}] |
Income From Continuous Operations | (151.81M) | (129.74M) | (202.12M) | (119.76M) | (9.06M) | [{"date":"2019-12-31","value":-15181100000,"profit":false},{"date":"2020-12-31","value":-12973900000,"profit":false},{"date":"2021-12-31","value":-20211500000,"profit":false},{"date":"2022-12-31","value":-11975800000,"profit":false},{"date":"2023-12-31","value":-905800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (151.81M) | (117.78M) | (190.86M) | (120.02M) | (9.06M) | [{"date":"2019-12-31","value":-15181100000,"profit":false},{"date":"2020-12-31","value":-11778200000,"profit":false},{"date":"2021-12-31","value":-19085700000,"profit":false},{"date":"2022-12-31","value":-12002100000,"profit":false},{"date":"2023-12-31","value":-905800000,"profit":false}] |
EPS (Diluted) | (3.56) | (2.55) | (3.37) | (1.94) | (1.77) | [{"date":"2019-12-31","value":-356,"profit":false},{"date":"2020-12-31","value":-255,"profit":false},{"date":"2021-12-31","value":-337,"profit":false},{"date":"2022-12-31","value":-194,"profit":false},{"date":"2023-12-31","value":-177,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MGNX | |
---|---|
Cash Ratio | 3.38 |
Current Ratio | 3.75 |
Quick Ratio | 3.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MGNX | |
---|---|
ROA (LTM) | -22.15% |
ROE (LTM) | -62.17% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MGNX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.55 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.45 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MGNX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.48 |
P/B | 1.69 |
Price/FCF | 4 |
EV/R | 0.26 |
EV/Ebitda | NM |
PEG | 0.01 |
MacroGenics Inc (MGNX) share price today is $3.165
Yes, Indians can buy shares of MacroGenics Inc (MGNX) on Vested. To buy MacroGenics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MGNX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of MacroGenics Inc (MGNX) via the Vested app. You can start investing in MacroGenics Inc (MGNX) with a minimum investment of $1.
You can invest in shares of MacroGenics Inc (MGNX) via Vested in three simple steps:
The 52-week high price of MacroGenics Inc (MGNX) is $21.88. The 52-week low price of MacroGenics Inc (MGNX) is $2.95.
The price-to-earnings (P/E) ratio of MacroGenics Inc (MGNX) is
The price-to-book (P/B) ratio of MacroGenics Inc (MGNX) is 1.69
The dividend yield of MacroGenics Inc (MGNX) is 0.00%
The market capitalization of MacroGenics Inc (MGNX) is $209.63M
The stock symbol (or ticker) of MacroGenics Inc is MGNX